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Background: Parkinson’s disease (PD) patients’ own knowledge and experience and access 
to information, in relation to advanced treatment methods, are very limited. The aim of this 
study was to map out PD patients’ perception about various advanced treatment methods, their 
availability and regional differences in medical care, and to investigate patients’ experience of 
their medication and quality of life.
Methods: A survey was sent to 4886 PD patients of the Swedish   Parkinson’s Disease Asso-
ciation covering demography, the patient’s illness, current treatment, received information 
about advanced treatment alternatives, and health status. Advanced PD was considered as 
patients diagnosed .5 years ago, using PD medication .5 times/day, and experiencing 
motor complications .2 hours/day.
Results: In total, 3327/4886 persons (68%) responded (57% men) of which 1300 (39%) were 
  classified as having advanced PD. Mean age was 71 years with a median disease duration of 8 
years. The   treating physician was a neurologist (86%) but varied between counties (96% to 52%) 
and was most frequent in urban areas. Doctor appointments were 1.7 times/year with regional 
  variation (2.1 to 1.1). Three out of four patients had heard of advanced treatment options and were 
interested, but were denied treatment. Only a small proportion of patients were informed of these 
by their physician. Nine percent were satisfied with their medication (including 4% of advanced 
patients). One third of patients experienced their general health as poor or very poor.
Conclusion: The majority of Swedish PD patients are treated by neurologists. Annual numbers 
of doctors’ appointments were low in an international context and can partly be explained by the 
shortage of neurologists and other trained specialists. Doctors only provided a small proportion 
of patients with advanced therapy information, despite patients’ interest. Hence, improvement 
is warranted regarding doctor appointments, information about various advanced treatment 
options, and their availability.
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Background
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
after Alzheimer’s disease – both have an inevitably progressive nature.1 Age is a 
prominent risk factor for both diseases, as is family history of the disease. Rural 
living,   exposure to pesticides or other toxins, and previous history of depression are 
other risk factors for PD whilst smoking appears to be a protective factor.2 There 
are as yet no   treatments available which curb or cure either disease.3 Currently, all 
clinical treatment is for symptom relief only. The initial treatment for both diseases is 
medication taken orally or delivered transdermally, though in the case of PD there are 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
433
OrIGINAL rESEArCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JMDH.S27180Journal of Multidisciplinary Healthcare 2011:4
other forms of administration, as well as brain surgery in the 
case of advanced disease.4,5 As the disease progresses, most 
PD patients eventually end up having difficulty controlling 
symptoms such as fluctuations, dyskinesia, and unpredict-
able so-called on-off episodes.3,6 These phenomena are 
often accompanied by non-motor symptoms from different 
organ systems such as the gastrointestinal and urogenital 
tract as well as neuropsychiatric and autonomic symptoms.7 
Advanced treatment can be considered when adequate symp-
tom relief is not provided by oral or transdermal medication. 
This is determined on an individual basis depending on the 
nature and severity of the symptoms, current and previous 
treatment, mental status, age, capability, and personal pref-
erence. Treatment alternatives for patients in an advanced 
disease state include deep brain stimulation (DBS),8 and 
two types of medication which are administered by con-
tinuous pump infusion. These are apomorphine,9 which is 
administered subcutaneously, and levodopa/carbidopa which 
is administered directly to the small intestine (Duodopa® 
[levodopa + carbidopamonohydrate for intestinal use]; Abbott 
Laboratories, Abbott Park, IL).10
The patients’ own knowledge and experience, especially in 
the later stages of the disease, how they perceive their situation, 
and access to information in relation to advanced treatment 
methods have until now been very limited.11,12 For this reason, 
a survey was carried out among members of the Parkinson’s 
Association to find out what information they had received 
about the various advanced treatment methods and their 
availability. The author also wanted to map out any regional 
differences in medical care and investigate how the patients 
experienced their medication and quality of life.
Materials and methods
A survey was sent to 4886 Parkinson’s patients who were mem-
bers of the Swedish Parkinson’s Disease Association. The sur-
vey included questions about demography, the patient’s illness, 
current treatment, what information the patient had received 
about advanced treatment alternatives, and who gave that infor-
mation, as well as an evaluation of their own health status. All 
questions were answered by multiple choice, however for some 
questions it was also possible to write extra comments.
The survey questions focused particularly on patients 
with advanced PD as it is for these patients that advanced 
treatment may be appropriate. For inclusion in this group the 
following three criteria were to be met:
•	 PD diagnosis .5 years ago
•	 uses PD medication at least 5 times per day
•	 experiences wearing-off of medication effect, “on-off” 
problems, dyskinesia or dystonia for at least two hours 
per day.
The survey was anonymous, however respondents were 
requested to include their postal code to enable regional 
comparisons to be made.
This study was approved by the Regional Ethical 
  Committee of Stockholm.
Results
The survey was completed by 3327 out of 4886 persons 
(68%) without any reminders.
The respondents consisted of 57% men and 43% women, 
which is the approximate gender distribution among PD 
patients in Sweden.13 The mean age was 71 years (35–100) 
with median illness duration of 8 years (35–100) (Table 1). 
Of all respondents, 1300 (39%) were classified as having an 
advanced disease state.
One factor which is crucial for the quality of care 
for PD patients is that the patient is seen by a   specialist 
in the field, ie, a neurologist or geriatrician who is 
  knowledgeable in the treatment of PD. The majority of 
survey respondents stated that their treating physician was 
a neurologist (86%) or   geriatrician (9%). A total of 7% of 
respondents reported that their treating physician was a 
general practitioner. Patients with advanced disease were 
mostly treated by neurologists (86%) and geriatricians 
(11%); only 5% of patients in this group were treated by 
a general practitioner.
There was great regional variation regarding which type 
of PD specialist patients were treated by. The percentage of 
patients who were seen by a neurologist varied from 96% to 
52% between different counties and was most frequent in 
the urban areas (Figure 2).
PD patients in the study saw a doctor on average 
1.7 times per year. Patients in the later stages of the disease 
were seen a little more often, on average 1.8 times per year. 
A considerable regional variation was seen here, with the 
appointment frequency being almost twice as high in some 
Table 1 Demographic variables of responding Parkinson’s disease 
patients
PD pts, total  
(n = 3326)
PD pts, advanced   
(n = 1300)
Mean age 71 (35–100) years 71 (39–100) years
Females/Males 43%/57% 43%/57%
Median PD duration 8 (1–46) years 11 (5–46) years
Abbreviations: PD, Parkinson’s disease; pts, patients.
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county council regions as others (with a range of 2.1 to 1.1 
appointments per year).
A little more than half of the respondents (56%) indicated 
that they took some kind of anti-PD mediation more than 
5 times per day. All patients in the advanced stages of the 
disease took medication more often than 5 times per day – 
this was also one of the criteria for inclusion in that group. 
Among the other patients, 70% took anti-PD medication 1–4 
times per day (Table 2).
Strong interest in advanced treatment 
options
Only 9% of respondents reported that they were satisfied with 
their medication – among patients with advanced disease 
this figure was only 4% (Figure 1). A significant number 
of patients also experienced their general health as poor or 
very poor: in the whole group 27%, and among patients with 
advanced disease, 38%.
In total around three quarters of the patients had heard 
of the three advanced treatment options, and in the group 
of patients in the later stages of the disease even more had 
done so (Table 3). More than half of the respondents had 
received information from Parkinsonjournalen, the members’ 
magazine published by the Swedish Parkinson’s Association. 
Other important information channels were: patient gather-
ings (25% in both the whole group and the late stages group); 
via television or the daily press (21% in the whole group and 
18% in the advanced disease group); and the Internet (8% in 
the whole group 6% in the advanced disease group).
Only a small proportion of patients had been informed 
of the three treatment options by their treating physician 
(Table 4) and only a little more than one in four patients in 
the advanced disease group had received this information 
from their doctor.
Among the respondents there were also some patients with 
experience of one of the three advanced treatment options. 
A total of 338 patients (10%) had received advanced 
treatment: DBS (n = 178; 5.3%), apomorphine pump (n = 83; 
2.5%) or Duodopa (n = 77; 2.3%).
Around half of respondents (47%) indicated that they 
were interested in being evaluated as to suitability for treat-
ment with one of the treatment options mentioned above – 
for the group of patients with advanced disease the figure 
was even higher (61%).
Many patients had however already been denied this 
treatment for varying reasons (Table 5). The most common 
reason was that the treating physician was of the opinion that 
the patient was not sufficiently unwell. However, 46 respon-
dents had been denied treatment for financial reasons.
Discussion
In this population of PD patients, it was found that the 
majority of patients were treated by physicians with   specialist 
knowledge of the disease but that the number of doctor’s 
visits per year was quite low and that this amount varied 
between different regions. The level of knowledge about 
advanced treatment was rather good among patients, but 
only one in four patients in the advanced disease group had 
been informed by their   doctor. This may be a problem since 
optimal patient care with patient participation requires that 
patients and their families are well informed.14–16 This lack 
of information may also contribute to the fact that only 
one in ten patients were very satisfied with their current 
medication and that three in ten rated their health as poor. 
The large variation in how often patients see their doctor, 
Table 2 Total number of administration times per day of anti-
PD medication, for patients with advanced disease and for the 
remainder
0 times 1–4 times 5–9 times .10 times
Total 32  
(1.0%)
1376  
(41%)
1696  
(51%)
172  
(5%)
Patients with  
advanced disease
0  
(0%)
0  
(0%)
1161  
(89%)
139  
(11%)
Other patients 32  
(2%)
1376  
(70%)
535  
(27%)
33  
(2%)
Abbreviation: PD, Parkinson’s disease.
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Figure 1 Only a small number of patients with Parkinson’s disease report that they 
are very satisfied with their treatment.
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according to the survey results, indicates that health care is 
unequally distributed between different groups and differ-
ent county councils. A higher frequency of doctor’s visits 
was mostly seen in metropolitan areas where access to neu-
rologists and geriatricians is   usually greatest.
Since PD is a progressive degenerative process for 
which there is currently no cure, it is hardly surprising that 
there is such a strong interest in the advanced, symptom-
alleviating treatment methods available for use in advanced 
disease. The potential for improvement is thus great. 
  Considering the critical importance of correct treatment for 
quality of life, it is surprising that only one in four patients 
with advanced disease had received such information from 
their doctor.
N: Neurologist
G: Geriatrician
P: Primary care physician
O: Other
University City Hospital
N: 85%
P: 3%
G: 15%
O: 1%
N: 84%
P: 6%
G: 4%
O: 6%
N: 81%
P: 5%
G: 14%
O: 2%
Västerbotten
N: 95%
P: 3%
G: 0%
O: 2%
Värmland
N: 91%
P: 4%
G: 3%
O: 0%
N: 90%
P: 5%
G: 3%
O: 2%
N: 96%
P: 2%
G: 0%
O: 0%
N: 89%
P: 7%
G: 1%
O: 4%
Örebro län
Västra Götaland
Halland
Kronoberg
N: 86%
P: 3%
G: 9%
O: 2%
Skåne
N: 88%
P: 10%
G: 2%
O: 2%
Blekinge
N: 87%
P: 3%
G: 10%
O: 1%
Kalmar län
N: 93%
P: 4%
G: 4%
O: 0%
Gotland
N: 52%
P: 1%
G: 50%
O: 4%
Jönköpings län
N: 92%
P: 3%
G: 5%
O: 1%
Stockholms län
N: 81%
P: 8%
G: 5%
O: 4%
Uppsala län
N: 87%
P: 8%
G: 5%
O: 2%
Västmanland
N: 89%
P: 8%
G: 2%
O: 2%
Gävleborg
N: 67%
P: 5%
G: 36%
O: 3%
Västernorrland
N: 81%
P: 11%
G: 6%
O: 4%
Norrbotten N: 84%
P: 5%
G: 10%
O: 2%
Sweden
N: 73%
P: 2%
G: 19%
O: 8%
Södermanland
N: 83%
P: 3%
G: 13%
O: 0%
Östergötland
Jämtland
Dalarna
Figure 2 Percentage of patients treated by medical specialists of Parkinson’s disease care in different counties of Sweden.
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That patients are denied treatment is sometimes appropri-
ate and this can often be motivated by the requirements and 
conditions which must be fulfilled for the various   treatment 
options. For example, prior to initiation of   treatment with 
medication delivered by pump (apomorphine and Duodopa) 
it must be established that the patient can manage the 
equipment, either by themselves or with the help of a family 
member.17,18 Apomorphine is furthermore considered less 
suitable for patients with neuropsychiatric symptoms.19 Brain 
surgery has an inferior effect and more side effects in older 
patients and is only in exceptional circumstances used in 
patients over the age of 70–75 years. One must also consider 
the high risk of adverse events with DBS including surgical 
site infections, and confused state of speech or impairment.20 
Cognitive impairment is common in patients in the later 
stages of the disease and can also render DBS and Duodopa 
inappropriate,21,22 whereas treatment with apomorphine in 
this regard could be more suitable. In summary, the different 
treatment options can be more or less suitable for individual 
patients.
Given the current scientific evidence and the cost of such 
treatment it is hardly appropriate to initiate treatment with 
DBS, apomorphine pump or Duodopa at an early stage when 
the regular medication is working well. Moreover, physicians 
should also emphasize the importance of, and encourage, 
exercise and training as complementary treatments for PD 
patients as well as awareness, diagnosis, and treatment of 
Table 3 Percentage of all patients/advanced patients aware of the 
different treatment options for advanced Parkinson’s disease
DBS/brain surgery Yes No
Total 76% 17%
Advanced disease 81% 13%
Infusion with apomorphine pump Yes No
Total 64% 24%
Advanced disease 74% 17%
Infusion with Duodopa® pump Yes No
Total 69% 21%
Advanced disease 76% 15%
Abbreviation: DBS, deep brain stimulation.
Table 4 Percentage of all patients/advanced patients who have 
received  information  from  their  treating  doctor  about  the 
different treatment options for advanced Parkinson’s disease
DBS/brain surgery Yes No
Total 20% 77%
Advanced disease 27% 73%
Infusion with apomorphine pump Yes No
Total 16% 84%
Advanced disease 26% 74%
Infusion with Duodopa pump Yes No
Total 17% 83%
Advanced disease 26% 74%
Abbreviation: DBS, deep brain stimulation.
non-motor symptoms, which most often do not respond 
to dopaminergic therapy. It can however hardly be seen as 
reasonable that 46 of the patients surveyed were denied 
treatment for financial reasons.23 It could be argued that 
the survey shows the patients’ subjective perception of the 
reasons for denial of treatment, which does not necessarily 
correspond to the reasons which the health care provider 
believes they have communicated to the patient. However, 
these patients feel that they are not a worthwhile investment 
of resources.
Although an overwhelming majority of respondents 
indicated that they are treated by a physician with special 
competence in the treatment of PD, the survey also revealed 
that 7% of the PD patients are treated by a general practitioner. 
Such physicians have usually only a few PD patients in their 
catchment area and therefore a limited experience of the disease 
and its treatment. Since respondents were able to choose more 
than one answer it is unclear whether the neurologist or 
geriatrician had continuing responsibility for their treatment or 
whether the patient was only occasionally seen by a specialist, 
or alternated between two doctors. One possible explanation 
for the fact that not all patients in the survey had been seen by 
a neurologist is the great shortage of neurologists in Sweden.24 
Compared to other European countries, Sweden has less 
neurologists per million inhabitants, with 33 versus 66 in 
Europe, 58 in Finland, and 49 in Norway.
Table 5 Number of PD patients being interested in advanced therapy but being denied due to noted reasons below
Not ill 
enough
Too  
severe  
disease
Old 
age
Impaired  
memory
Mental  
symptoms  
(hallucinations,  
depression)
Speech  
difficulties
Difficulties  
handling the  
equipment
Social  
reasons
Geographic  
reasons
Economic  
reasons  
(expensive  
treatment)
Other
Total 200 29 102 58 64 57 55 7 3 46 176
Advanced  
disease
98 19 59 36 35 30 37 2 2 33 100
Abbreviation: PD, Parkinson’s disease.
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Limitations
The survey provides a unique insight into patients’ own expe-
riences of their illness, the information they receive about the 
various treatment options, and what treatment options they 
are offered. In only addressing the survey to members of the 
Parkinson’s Association a selection has of course been made. 
This selection can however result in only the most active 
patients, who have of course already shown themselves to be 
active enough to join the Swedish PD Association, responding 
to the survey. Then the results must be considered as even 
more discouraging since the less active non-members of the 
association maybe would have scored less favorably on the 
survey. However, the respondents constitute one sixth of the 
Swedish population of patients diagnosed with PD.13 The 
chosen method had a high response frequency without the 
use of reminders and respected the patients’ integrity. This 
would not have been the case if the patients had been tracked 
and recruited via Swedish Pharmaceutical dispensing data 
regarding anti-PD medication, which could have been an 
alternative method.
Pharmaceutical information was not obtained from the 
patients, nor were any assessments of disease severity under-
taken, the latter for methodological reasons. However, despite 
this lack of information, the patients’ own experiences stated 
that only a minority of them were satisfied with their current 
medication. The same research design as that discussed here 
has also recently been used by German PD researchers.25
Future research
Future research should aim at mapping early diagnostic signs 
of PD such as smell dysfunction, REM sleep behavior disorder, 
and obstipation, as well as finding neuroprotective drugs. 
  However, a current problem with early detection and diagnosis 
of PD is that there are no commercially available neuroprotec-
tive drugs, although there are some indications that MAO-B 
inhibitors may have such properties.26 It is likely that there is 
no one drug or one solution, rather, that an approach using 
a combination of drugs with different targets, possibly with 
synergistic effects, will prove effective. Also, more research 
should be performed on the common use and possible effects 
of complementary and alternative medicines, which could 
contribute to the armamentarium of anti-PD treatment.27
Conclusion
The majority of Swedish PD patients are treated by physi-
cians with specialist knowledge of the disease. The number 
of times per year that patients are seen by a doctor is low in 
an international context and can most likely be explained 
by the shortage of neurologists and other trained specialists. 
This may also contribute to the regional differences shown. 
Doctors only provided a small proportion of patients with 
advanced therapy information, despite patients’ interest.
This study has shown deficiencies and areas which can 
be improved within the area of PD management in Sweden. 
Knowledge of different aspects of PD will hopefully be 
greatly improved as a result of the Swedish National Neu-
rology Registry which was initiated during 2011 and which 
will include PD. Data from the registry will be available for 
use by patient organizations, health care providers and deci-
sion makers, with the overall aim being the improvement of 
patient care.
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